OBJECTIVE： To evaluate the efficacy and safety of salmeterol/fluticasone combined with montelukast versus salmeterol/fluticasone in the treatment of cough variant asthma， and to provide reference for evidence-based reference in clinic. METHODS： Retrieved from Cochrane library， PubMed， Chinese Journal Full-text Database， VIP and Wanfang database， randomized controlled trials （RCTs） about therapeutic efficacy （total response rate， marked improvement rate， cough disappearance time， 6-12 months recurrence rate） and safety （the incidence of ADR） of salmeterol/fluticasone combined with montelukast （trial group） vs. salmeterol/fluticasone （control group） in the treatment of cough variant asthma were included. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with Cochrane system evaluation manual 5.1.0. RESULTS： Totally 10 RCTs were included， involving 976 patients. Results of Meta-analysis showed the total response rate [RR＝1.22，95％CI（1.16，1.29），P＜0.001] and marked improvement rate [RR＝1.38，95％CI（1.22，1.56），P＜0.001] of trial group were significantly higher than those of control group； the cough disappearance time was significantly shorter than control group [MD＝－3.07，95％CI（－3.54，－2.59），P＜0.001]， and 6-12 months recurrence rate was significantly lower than control group [RR＝0.24，95％CI（0.11，0.54），P＜0.001]， with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups [RR＝1.58，95％CI（0.99，2.51），P＝0.05]. CONCLUSIONS： The salmeterol/fluticasone combined with montelukast is better than of salmeterol/fluticasone in the treatment of cough variant asthma， but great importance should be attached to the occurrence of adverse events when using drug combination.